MYGN - Myriad Genetics, Inc.
| Previous Close | 14.53 |
| Open | 14.65 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 1200 |
| Day's Range | 14.59 - 15.63 |
| 52 Week Range | 9.24 - 48.40 |
| Volume | 1,661,292 |
| Avg. Volume | 1,075,688 |
| Market Cap | 1.132B |
| Beta (5Y Monthly) | 1.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.01 |
| Earnings Date | Aug. 11, 2020 - Aug. 17, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.67 |
- GlobeNewswire
Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, today announced the presentation of two new studies at the 2020 American Society of Clinical Oncology (ASCO) annual meeting demonstrating the ability of Myriad’s riskScore® test to provide personalized breast cancer risk information that allows patients and physicians to make better informed clinical treatment decisions. “We are excited to further demonstrate Myriad’s commitment to providing the best possible risk assessment tools to patients through innovation,” said Nicole Lambert, president of Myriad Oncology, Myriad Women’s Health and Myriad International. “The validation data we are presenting at ASCO this year will support a broader launch of riskScore to even more women in the coming year with more personalized information and the unique ability to modify carrier risk through a clinically validated tool.”
- GlobeNewswire
Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D.
Myriad Genetics, Inc. (MYGN), a global leader in molecular diagnostics and precision medicine, today announced the election of Daniel K. Spiegelman, age 61, to its Board of Directors, effective immediately, expanding the Board to nine members. Additionally, Mr. Spiegelman was appointed to the audit committee of Myriad’s Board. Mr. Spiegelman has served as a Chief Financial Officer in several diversified biotechnology companies spanning 30 years.
- Zacks
Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories
Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories
- Zacks
Dump These 4 Toxic Stocks or Sell Short for Timely Profits
Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.
- GlobeNewswire
Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study
Cerecor Inc. (CERC) and Myriad Genetics Inc. (MYGN) today announced that levels of novel cytokine, LIGHT, were highly correlated with disease severity and mortality in a COVID-19 acute respiratory distress syndrome (ARDS) biomarker study. The biomarker study was conducted using the serum samples of 47 hospitalized COVID-19 patients and 30 healthy controls from Hackensack Meridian Health Network.
- GlobeNewswire
Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the BRACAnalysis CDx® test for use as a companion diagnostic by healthcare professionals to identify men with metastatic castration-resistant prostate cancer (mCRPC) who are eligible for treatment with Lynparza® (olaparib). Lynparza is approved for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
- Zacks
Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem
Within Molecular Diagnostics, Myriad Genetics (MYGN) registers strong sales for EndoPredict, myChoice CDx and BRACAnalysis CDx.
- Zacks
Biotech ETFs to Gain From Latest Advancements in Cancer Drugs
The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.
- GlobeNewswire
Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the myChoice CDx® test for use as a companion diagnostic by healthcare professionals to identify advanced ovarian cancer patients with positive homologous recombination deficiency (HRD) status, who are eligible or may become eligible, for first-line maintenance treatment with Lynparza (olaparib) in combination with bevacizumab. Lynparza (olaparib) is a novel PARP inhibitor jointly developed and commercialized by AstraZeneca (LSE/STO/NYSE: AZN) and Merck, known as MSD outside of the U.S. and Canada.
- Zacks
Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View
Myriad Genetics (MYGN) reports revenue declines in both reporting segments in Q3 resulting from coronavirus-led business disruptions.
- Thomson Reuters StreetEvents
Edited Transcript of MYGN earnings conference call or presentation 5-May-20 8:30pm GMT
Q3 2020 Myriad Genetics Inc Earnings Call
- Motley Fool
Myriad Genetics Inc (MYGN) Q3 2020 Earnings Call Transcript
Image source: The Motley Fool. Myriad Genetics Inc (NASDAQ: MYGN)Q3 2020 Earnings CallMay 5, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings, and welcome to the Myriad Genetics Third Quarter 2020 Financial Earnings Call.
- GlobeNewswire
Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results
Total Third-Quarter Revenues of $164.0 MillionThird-Quarter Diluted EPS of ($1.55) and Adjusted EPS of ($0.08) SALT LAKE CITY, May 05, 2020 -- Myriad Genetics, Inc. (NASDAQ:.
- GlobeNewswire
Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020
SALT LAKE CITY, April 28, 2020 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal.
- Zacks
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive Disorder
Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the publication of a meta-analysis of four clinical trials demonstrating that the GeneSight® Psychotropic test significantly improves clinical outcomes among patients with major depressive disorder (MDD). “Many commercial insurers and health technology assessors in the United States and internationally consider meta-analyses the highest level of clinical evidence for the treatment of depression,” said Bryan Dechairo, Ph.D., executive vice president of Clinical Development at Myriad. The analysis included data from four prospective, controlled trials that evaluated the clinical utility of the GeneSight test in 1,556 people with MDD and who had at least one prior antidepressant medication failure.
- GlobeNewswire
Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, announced today that due to the impact of the global COVID-19 pandemic, the company is withdrawing its fiscal year 2020 financial guidance. “Prior to mid-March we were experiencing volume trends consistent with our expectations across all products; however, recent social distancing guidelines have had a significant impact on test volume trends in late March and into the fiscal fourth-quarter,” said R. Bryan Riggsbee, interim president and CEO and chief financial officer at Myriad Genetics. In responding to the pandemic, Myriad has made several changes to its business practices to promote the safety of both customers and employees including ceasing in-office sales calls and implementing virtual selling, granting all non-essential personnel the ability to work from home, enabling direct sample collection for patients and implementing policies to improve laboratory personnel safety.
- Zacks
Myriad Genetics' (MYGN) BRACAnalysis Gets Japan Reimbursement
Myriad Genetics (MYGN) launches BRACAnalysis Diagnostic System in Japan, after receiving reimbursement for the system, which will enable easier identification of HBOC patients.
- GlobeNewswire
Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced that it has received reimbursement and launched the BRACAnalysis® Diagnostic System (i.e., “BRACAnalysis”) in Japan to help physicians determine which people affected with breast and ovarian cancer have Hereditary Breast and Ovarian Cancer (HBOC) syndrome and qualify for additional diagnostic and medical management. BRACAnalysis previously was approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) in November 2019 for this indication.
- GlobeNewswire
Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced it has submitted a supplementary application with the Japanese Ministry of Health Labour and Welfare for its BRACAnalysis® Diagnostic System (i.e., “BRACAnalysis”) to be used as a companion diagnostic to help to identify people with metastatic pancreatic or metastatic castration-resistant prostate cancer who have germline BRCA1 and BRCA2 mutations and may be candidates for targeted therapy with the PARP inhibitor, Lynparza® (olaparib), subject to regulatory approval. “Today’s regulatory filing potentially will expand the approved indications for BRACAnalsyis as companion diagnostic test in Japan,” said Gary King, executive vice president of International Operations at Myriad.
- Simply Wall St.
A Look At The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
How far off is Myriad Genetics, Inc. (NASDAQ:MYGN) from its intrinsic value? Using the most recent financial data...
- GlobeNewswire
Myriad Announces Board of Directors Leadership Transition
Myriad Genetics, Inc. (MYGN), a global leader in molecular diagnostics and precision medicine, announced today that S. Louise Phanstiel has been appointed as chair of the Board of Directors. John T. Henderson, M.D., will remain on the Board of Directors.
- Zacks
Myriad Grows Internationally, Hereditary Cancer Revenues Soft
Myriad Genetics (MYGN) registers soft Hereditary Cancer, GeneSight, Vectra as well as Prenatal revenues in second-quarter fiscal 2020.
- GlobeNewswire
NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer
Myriad Genetics, Inc. (MYGN), a global leader in molecular diagnostics and precision medicine, announced that the National Comprehensive Cancer Network (NCCN) updated its professional guidelines for prostate cancer to recommend biomarker-based testing for men with unfavorable intermediate and high-risk disease. Myriad’s Prolaris test was one of only two prognostic tests for prostate cancer recommended by NCCN for the new expanded indications and is now broadly recommended for use in low, intermediate and high-risk disease. “NCCN’s endorsement of Prolaris testing in unfavorable intermediate and high-risk disease is a major step forward for men and will help in expanding access to testing,” said Todd D. Cohen, M.D., vice president of Medical Affairs for Urology at Myriad Genetics.
- Zacks
Myriad (MYGN) Down 44.1% Since Last Earnings Report: Can It Rebound?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
